A phase 2 clinical study of FB-102 in the patients with celiac disease
Latest Information Update: 26 Jun 2025
At a glance
- Drugs FB-102 (Primary)
- Indications Coeliac disease
- Focus Therapeutic Use
Most Recent Events
- 26 Jun 2025 New trial record
- 23 Jun 2025 According to Forte Biosciences media release, The Phase 2 celiac disease study is initiating with a topline readout expected in 2026.